Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10172311 | 0.83 | KDM4E (0.38) | KDM4ECHEK1CHEK2 | |
| SCHEMBL620050 | 0.80 | CHEK1 (0.54) | CHEK1CHEK2KCNH2 | |
| SCHEMBL12122932 | 0.80 | CHEK1 (0.42) | KDM4EGAAMAPTIRAK4TYK2 | |
| SCHEMBL10172315 | 0.77 | IDO1 (0.41) | CHEK1KCNH2 | |
| SCHEMBL10172309 | 0.74 | CHEK1 (0.49) | CHEK1CHEK2KCNH2 | |
| SCHEMBL10172314 | 0.74 | CHEK1 (0.49) | CHEK1CHEK2KCNH2 | |
| SCHEMBL10172288 | 0.74 | CHEK1 (0.49) | CHEK1CHEK2KCNH2 | |
| SCHEMBL12122419 | 0.73 | UHRF1 (0.41) | — | |
| SCHEMBL10220530 | 0.71 | CHEK1 (0.53) | IRAK4CHEK1CHEK2JAK2JAK1 | |
| SCHEMBL10172337 | 0.71 | CHEK1 (0.44) | CHEK1CHEK2JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367658-B2 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-02-05 | — | — | US | disclosed |
| US-20120040967-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-8058045-B2 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-11-15 | — | — | US | disclosed |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040967-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CHEK1, CHEK2, PLK1 | KDM4E 1193/4885GAA 1694/4885MAPT 594/4885 |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CHEK1, CHEK2, BUB1B | KDM4E 1296/4885GAA 2118/4885MAPT 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.